Malaysia vs Mozambique: Average cost of drugs for extensively drug-resistant tuberculosis
Malaysia
10,000 constant 2022 US$
in 2024
Mozambique
5,675 constant 2022 US$
in 2024
Malaysia rank
4th
Mozambique rank
7th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Malaysia
- Mozambique
How they compare
Malaysia currently reports 10,000 constant 2022 US$ against 5,675 constant 2022 US$ in Mozambique, a difference of 4,325 constant 2022 US$.
That makes Malaysia's figure about 1.8 times Mozambique's.
Across all 8 years both countries report, Malaysia has been ahead every year.
Malaysia ranks 4th and Mozambique ranks 7th of 56 countries.
Malaysia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Malaysia | Mozambique | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 45,000 constant 2022 US$ | 3,564 constant 2022 US$ | 41,436 constant 2022 US$ | Malaysia |
| 2020s | 22,000 constant 2022 US$ | 4,938 constant 2022 US$ | 17,062 constant 2022 US$ | Malaysia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Malaysia or Mozambique?
- Malaysia, at 10,000 constant 2022 US$ against 5,675 constant 2022 US$ in Mozambique as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Malaysia and Mozambique?
- 4,325 constant 2022 US$, with Malaysia ahead.
- How many years of comparable data are there for Malaysia and Mozambique?
- 8 years are reported by both, from 2017 to 2024.
- How do Malaysia and Mozambique rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Malaysia ranks 4th and Mozambique ranks 7th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.